eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
09/30/22
Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.
09/07/22
Eyenovia to Present at Upcoming Healthcare Conferences
09/06/22
Eyenovia to Participate in Multiple Medical Meetings in September
Upcoming Events
There are currently no events scheduled.